Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Cervarix in Healthy Chinese Females
NCT00996125Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection comparing Cervarix Group with Placebo Group (2 arms). Primary endpoint: Geometric Mean Titers (GMTs) for Antibodies Against Human Papillomavirus (HPV)-16/18 Antigens at Month 7. Started Oct 2009; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00996125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996125.